AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 131 min read$JNJ

Johnson & Johnson Q3 2026: Revenue $25.4B, Adjusted EPS $2.59; Raises 2026 Guidance

Johnson & Johnson reported Q3 2026 revenue of $25.4B, up 5.9% YoY, and adjusted EPS of $2.59. The company raised full-year 2026 guidance, with midpoint sales now expected at $101.2B and adjusted EPS at $11.10. Growth was driven by Innovative Medicine and MedTech segments, with several regulatory approvals and strategic transactions noted.

Original reporting
tradingview.com
Published Oct 13, 2026, 12:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Johnson & Johnson Q3 2026: Revenue $25.4B, Adjusted EPS $2.59; Raises 2026 Guidance — source image
Source · tradingview.com
Decision brief

The 30-second read

$JNJBullishHigh
01

Why it matters

The earnings beat and guidance raise provide a clear catalyst for short-term buying interest.

02

Market read

The earnings release is a material event for the stock and the broader healthcare sector.

03

What to watch

One-time special charge from litigation resolution could mask underlying earnings weakness.

Relevance 9/10Novelty 9/10Timing: immediate today

Background

Johnson & Johnson released its Q3 2026 earnings, highlighting revenue growth, regulatory approvals, and strategic acquisitions.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson disclosed Q3 2026 results and raised full-year guidance, a primary earnings release for a large-cap company.

Expected impact

upward pressure as investors price in higher revenue and EPS guidance

Evidence & confidence

The company increased full-year sales midpoint to $101.2B and adjusted EPS to $11.10, indicating robust performance.

Market effects

Sector

Strong MedTech and Innovative Medicine results may lift healthcare sector peers.

Regional

U.S. healthcare stocks could see modest gains following the upbeat guidance.

Global

Global investors tracking large-cap pharma may adjust exposure to the sector.

Counterpoint

What could challenge this read

If the guidance raise is already priced in, the stock may face limited upside.

Key entities

  • company
    Johnson & Johnson

    Large-cap healthcare conglomerate reporting Q3 results.

Read at source← All news

Also covered by

4 outlets

Related articles

OCT 13
$JNJHighAI 9/10

Johnson & Johnson reports Q3 2026 results, raises 2026 guidance

JOHNSON & JOHNSON (JNJ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com For immediate release Johnson & Johnson reports Q3 2026 results, raises 2026 guidance • 2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational grow

SEC EDGAR 8-K6 min
OCT 13
$JNJHighAI 8/10

Why is Johnson & Johnson stock sliding today?

Johnson & Johnson (JNJ) stock fell 2.5% in pre-market trading despite a solid Q3 2026 earnings report. Adjusted EPS beat estimates at $2.59, with revenue of $25.4B, up 5.9% YoY. GAAP EPS dropped 95.9% to $210M due to one-time charges. The company raised its full-year guidance to $11.05–$11.15 adjusted EPS. Medical device sales grew slowly, while pharmaceutical sales rose 7.7%. The stock traded below moving averages, and analysts revised EPS estimates downward.

investing.com2 min
OCT 13
$JNJMedAI 8/10

Johnson & Johnson beats estimates, raises 2026 guidance

Johnson & Johnson (JNJ) reported Q3 earnings of $2.59 per share, beating estimates by $0.06, with revenue at $25.4B, up 5.9% YoY. The company raised its 2026 adjusted EPS guidance to $11.05-$11.15 and revenue guidance to $101.0-$101.4B. Shares rose 0.1% post-announcement. Growth was driven by the Innovative Medicine and MedTech segments, with U.S. sales up 9.1% and international sales up 1.5%.

finance.yahoo.com2 min